Zenas Biopharma Inc (ZBIO)

$9.61 +0.06 (0.63%)
Market Cap 399.52M
Revenue (ttm) 5.00M
Net Income (ttm) -156.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,139.80%
Debt to Equity Ratio 0.00
Volume 105,300
Avg Vol 175,498
Day's Range N/A - N/A
Shares Out 41.83M
Stochastic %K 24%
Beta N/A
Analysts Strong Sell
Price Target $32.38

Latest News on ZBIO

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Jun 2, 2025, 1:26 PM EDT - 3 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 2, 2025, 4:00 AM EDT - 4 days ago

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

May 31, 2025, 8:55 AM EDT - 6 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 7:05 AM EDT - 8 days ago

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

Reminder from Cohen Milstein: Zenas BioPharma (ZBIO) Lead Plaintiff Deadline in ZBIO Stock Drop Suit Approaching

May 15, 2025, 3:10 PM EDT - 21 days ago

Reminder from Cohen Milstein: Zenas BioPharma (ZBIO) Lead Plaintiff Deadline in ZBIO Stock Drop Suit Approaching

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 15, 2025, 7:05 AM EDT - 22 days ago

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

May 14, 2025, 3:06 PM EDT - 22 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Zenas BioPharma Investors: Cohen Milstein Highlights June 16 Deadline to Seek Lead Plaintiff Role in Securities Lawsuit

May 13, 2025, 4:20 PM EDT - 23 days ago

Zenas BioPharma Investors: Cohen Milstein Highlights June 16 Deadline to Seek Lead Plaintiff Role in Securities Lawsuit

Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit

May 5, 2025, 2:48 PM EDT - 4 weeks ago

Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit

Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related Fraud

May 1, 2025, 3:08 PM EDT - 5 weeks ago

Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related Fraud

Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses

Apr 22, 2025, 10:37 AM EDT - 6 weeks ago

Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses

Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses

Apr 21, 2025, 12:33 PM EDT - 6 weeks ago

Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. (ZBIO)

Apr 17, 2025, 8:00 PM EDT - 7 weeks ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 17, 2025, 4:20 PM EDT - 7 weeks ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst

Apr 7, 2025, 3:08 PM EDT - 2 months ago

Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Apr 7, 2025, 7:05 AM EDT - 2 months ago

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Mar 20, 2025, 2:54 PM EDT - 2 months ago

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Mar 17, 2025, 7:05 AM EDT - 2 months ago

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Feb 5, 2025, 7:05 AM EST - 4 months ago

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 8:00 AM EST - 4 months ago

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 12, 2024, 7:10 AM EST - 7 months ago

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Nov 12, 2024, 7:05 AM EST - 7 months ago

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Nov 7, 2024, 7:05 AM EST - 7 months ago

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

Sep 19, 2024, 4:15 PM EDT - 9 months ago

Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering